PKN3 and metastatic neoplasm: Moreover, a therapeutic agent that targets PKN3 by RNA interference (siRNA Atu027) has already completed Phase I clinical trials in a study with patients exhibiting different solid advanced and metastatic tumors, showing very promising results without any adverse effects (Schultheis et al., 2014), further supporting the validity of this strategy.